UNSPSC 51152053: Dantrolene sodium anhydrous

This classification denotes a muscle relaxant with the molecular formula C14H9N4O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28F0G1E0VF, chemically known as 1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin sodium salt, but more generally known as dantrolene sodium anhydrous, which bears US NIH Compound Identifier 6604100. European Medicines Agency schedules dantrolene sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06903MIG.

Most nations, for tariff purposes, schedule dantrolene sodium anhydrous under HS 29349990. SMILES: C1CC(CCC1C2CCC(O2)/C=N/N3CC(=O)[N-]C3=O)[N+](=O)[O-].[NA+].

UNSPSC 51152053 Dantrolene sodium anhydrous is a Commodity code that in recent state and local activity covers procurement of pharmaceutical products and related medical supplies for public health initiatives, though the recent opportunities posted under this code do not clearly align with dantrolene sodium itself. Seminole County, Florida issued an IFB in June 2026 to procure naloxone and safe drug deactivation systems — 1,900 units of naloxone and 800 deactivation units annually through quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted a Request for Information in April 2026 soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to evaluate contracting models outside traditional pharmacy benefit manager arrangements. The issuing bodies span county health departments and state health agencies, reflecting a mix of local and state-level procurement for pharmaceutical inventory and pharmacy program management.

Geographic activity centers on Florida and Texas based on the recent postings. The Seminole County opportunity (IFB60459723LAS, response deadline July 26, 2023) requires vendors to submit electronic bids with unit costs, drug-free workplace certification, E-Verify compliance, and proof of required insurance; the contract term runs two years with an optional one-year renewal and includes a three-month probationary termination window. The Texas RFI (HHS0017013, posted April 3, 2026) seeks vendor experience with direct contracting for self-insured employers and health plans, negotiated net pricing models, and outcomes-based agreements, with no formal evaluation criteria or award value specified at the information-gathering phase. Neither opportunity specifies set-aside designations for disadvantaged enterprises. The mismatch between the code's nominal pharmaceutical compound and the actual work being solicited — naloxone distribution and pharmacy program restructuring — suggests this code shows limited recent activity strictly aligned with dantrolene sodium procurement.